Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rigel Pharmaceuticals
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
2. Subject must have completed all 24 weeks of participation in the study C-935788-057.
You may not be if
1\. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
Clareo Health | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
